The European Medicines Agency (EMA) and the US FDA have set up a new ‘cluster’ on rare diseases to share experiences and best practices on each other’s regulatory approach to the development of medicines for these diseases.
While rare diseases are estimated to affect 30 million people in the EU and approximately the same number in the US, each disease individually concerns a limited number of patients.
Therefore, global collaboration in this area is particularly important to ensure that the limited number of studies conducted can benefit all patients regardless of where they live, the EMA said.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.